TRIUMPH-6

Active not recruitingPhase 3

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity

Lead sponsor

Eli Lilly and Company

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

—

Enrollment

643

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06859268

Org study ID27268

Secondary IDJ1I-MC-GZQBEli Lilly and Company

Timeline

Milestones

Study first posted2025-03-05actual

Study start2025-03-05actual

Last update posted2026-03-03actual

Primary completion2028-04estimated (month precision)

Study completion2028-04estimated (month precision)

Assets

Investigational agents

Retatrutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight

Exclusion criteria

•Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days before screening

•Have a prior or planned surgical treatment for obesity

•Have a prior or planned endoscopic procedure and/or device-based therapy for obesity

•Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes

•Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)

•Have had within the past 90 days before screening:

–acute myocardial infarction

–cerebrovascular accident (stroke)

–hospitalization for unstable angina, or

–hospitalization due to congestive heart failure

•Have New York Heart Association Functional Classification Class IV congestive heart failure

•Have a history of chronic or acute pancreatitis

•Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Patient-reported / QoL

Weight & body composition

3 endpoints

Primary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Week 0, Week 116

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Waist Circumference

Time frame:Week 0, Week 116

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Percentage of Body Weight Reduction Achieved at Week 80 that is Maintained at Week 116

Time frame:Week 0, Week 80, Week 116

Body weight, % change

percent change from baseline, improvement

Patient-reported / QoL

1 endpoint

Secondary/protocol endpoint

Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)

Time frame:Week 0, Week 116

IWQOL-Lite total

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.